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Abstract
Background: The ameloblastic carcinoma is a rare malignant odontogenic tumor which rather
occurs in the mandible than in the maxilla. Its rarity and in this context somewhat speculative
histopathogenesis may account for diagnostic difficulties. Current classifications do not consider
benign histopathological features at the primary and malignant features at the metastatic tumour
site. Based on an evidence-based literature review, a recommendation for a novel classification is
presented.
Methods: An evidence-based literature review over the last 60 years regarding ameloblastic
carcinoma of the maxilla was conducted.
Results: An overall of 26 cases were found (mean age: 54.4 (583 years); male to female ratio: 2.7
to 1). In 54% the primary diagnosis was ameloblastic carcinoma, 34.6% revealed pulmonary
metastases, however, only in one patient cervical lymph node metastasis could be found. Whereas
two cases did not reveal malignant histopathology at the primary, they revealed malignant features
at their metastatic sites. Nineteen of 26 patients (73,1%) were controlled during a median follow-
up time of 54,3 months (6 to 156 months); 6 patients died of disease after a median time of 62,7
months (7 to 156 months) after initial diagnosis.
Conclusion: It is of utmost importance to be aware of that ameloblastomas may be capable to
degenerate into a "malignant" disease with recurrence and metastasis. In addition to local long-term
control, special attention should be paid to potential pulmonary involvement.
Introduction
Ameloblastomas, representing 1% of all jaw tumours, are
considered to be benign, but locally aggressive odon-
togenic epithelial neoplasms [1]. The largest review was
performed in 1995 by Reichart et al [1] comprising 3677
cases. Amongst others, calcifying epithelial odontogenic
tumor, metastatic carcinoma of the jaw and keratocystic
odontogenous tumours may come into consideration as
differential diagnoses.
The maxillary mandibular ratio of ameloblastoma is 5 to
1, in favour for the mandible. Its most common site of
occurrence is the mandibular molar region [1,2]. More
than 50% of recurrence appears within the first 5 years
after primary surgery[1]. Even though ameloblastomas are
well studied and documented, little is known about their
malignant features. This is reflected in the fact that
whereas more than 3600 cases of ameloblastomas have
been described in the literature [3], fewer than 60 cases of
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ameloblastic carcinoma have been reported, among
which two thirds occurred in the mandible.
In regard to malignancy, one must be aware of the differ-
ence between malignant ameloblastoma and ameloblas-
tic carcinoma. The latter reveals malignant
histopathological features independent of the presence of
metastasis [4], whereas malignant ameloblastomas metas-
tasize as well differentiated benign cells [5]. To a high per-
centage (7085%) metastases of ameloblastoma occur in
the lungs [6,7].
Both aetiology of this rare carcinoma and the question
whether this type of carcinoma originates from an amel-
oblastoma or represents a separate entity are still contro-
versially discussed. However, most of the published data
involving ameloblastic carcinoma of the maxilla result
from single-case reports; prospective data or data from
multi-centre studies are lacking. Treatment guidelines lack
of results from long-term follow-up, because most case
reports cover a time-span less than 5 years after the pri-
mary operation. Moreover, often a long-term follow-up is
not possible due to advanced age of patients.
In comparison to ameloblastic carcinomas of the mandi-
ble, maxillary ameloblastic carcinomas have not been
well studied because of the lack of available data.
Therefore the aim of the here presented evidence based lit-
erature review is to collect clinical features and treatment
results of maxillary ameloblastic carcinoma over a period
of 60 years in order to implement a novel classification for
this type of carcinoma.
Methods
Electronic databases (Medline and Cochrane) were
searched using a set of predetermined keywords. The
search strategy was initially developed and implemented
for PubMed but revised appropriately to suite the other
database. A combination of free text terms with Boolean
operators and truncation were used. No restriction was
placed on the year or language of publication. The search
strategy was devised in consultation with a senior librar-
ian.
The citations retrieved from each database were exported
into the EndNote bibliometric management software.
Duplicates were discarded. The titles and abstracts were
screened and the hard copies of all potentially relevant
articles were retrieved. Their reference lists were manually
searched for any related articles.
Results
During 60 years (1948  2008), an overall of 26 cases of
maxillary ameloblastic carcinomas have been described
(Table 1) [8-28]. In 3 cases only, a description of the
autopsy result could be obtained. The mean age was 54.4
years with a marked prevalence in the group from 41 years
to 80 years (69.2%) (Fig. 1); female to male ratio was 1 to
2.7. The predominant chief complaint was swelling (Fig.
2). Regarding the tumour localisation, 44% were found in
the left maxilla, and 32% in the right side of maxilla (Fig.
3); in 54% the first specimen revealed directly an amelob-
lastic carcinoma, but in 15% a follicular ameloblastoma
was first found (Fig. 4). 26,9% revealed pulmonary metas-
tases and in 23% local recurrence was detected (Fig. 5).
77% of the patients underwent a median follow-up
period of 54.3 months (6  156 months) while 23% died
of disease after a median time of 62,7 (7 months-10 years)
months after initial diagnosis (Fig. 5).
Discussion
Maxillary ameloblastic carcinomas are very rare. Therefore
features like metastasis pattern, histopathological factors,
and gender predilection  in contrary to amelobalstic carci-
nomas of the mandible  have only been presented in sin-
gle case reports. Hence the intention of this study was to
collect aspects of clinical appearance and to compare
these results with the current classifications of ameloblas-
tic carcinomas. Whereas some authors state no gender
predilection in ameloblastomas [2], a preponderance of
males was found in the here presented study with a
female-male ratio of 1 to 2.7. The first clinical sign in
61.5% of cases was swelling; bleeding, ulceration or fis-
tula was only found in 15.4%. It might be assumed that
therefore patients presented already with a progressive
form at first sight.
Progressive types of ameloblastic carcinomas may also be
associated with the degree of aggressiveness being possi-
bly defined as cortical bone perforation, invasion of soft
tissue, recurrences, and metastases. Both pathways hae-
Age distribution showing the occurrence of maxillary amel- oblastic carcinoma Figure 1
Age distribution showing the occurrence of maxillary 
ameloblastic carcinoma.
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matogenous as well as lymphatic seem to be possible,
even though the latter is rare. Among the reviewed cases,
34.6% revealed metastases and 23.1% local recurrences.
In only one case neck lymph nodes were involved. In
26.9% pulmonary metastases occurred. This high percent-
age emphasizes the importance to detect pulmonary
metastases either by computertomography or PET-scans
as well as the need for long-term follow-up. Besides these
screening methods, increasing serum calcium has been
considered to be a predictor of metastases [12], even
though such an increase might be unspecific due to an
osteolysis.
Histopathologically two factors have been discussed as
predictors for metastasis and/or aggressive behaviour:
granular cell change; an extensive clear cell component
[15,29,30]. However, these histopathological features
have not been investigated in all case reports and there-
fore general interpretation is lacking evidence. The diffi-
culty for this seems to be the difference whether the
carcinoma is a different entity or whether it has originated
from an ameloblastoma.
In the present study (Fig. 4) 50% was determined to be an
ameloblastic carcinoma, not excluding, however, the
potential development of an undetected ameloblastoma.
Especially this problem has not been considered in cur-
rent classifications (Table 2). Besides the classification of
the WHO [31], two other current classifications have been
developed (Table 1) so far. A significant disadvantage,
however, remains the presupposition that the origin,
including the histopathogenesis of ameloblastic carci-
noma, is still unknown.
Therefore, considering its unknown origin and the phe-
nomenon that has been described in the literature [8,10],
we recommend a modification of the current classifica-
tion (Table 2), where a primary ameloblastoma is fol-
lowed by secondary metastasis with histopathological
features of malignancy and without evidence of malig-
nancy in the primary localization.
Distribution of first symptoms Figure 2
Distribution of first symptoms.
Distribution of primary tumor localisation Figure 3
Distribution of primary tumor localisation.
Histopathological diagnosis of the first specimen Figure 4
Histopathological diagnosis of the first specimen.
Time (months) of local recurrence (red) and metastases  (blue) appeared Figure 5
Time (months) of local recurrence (red) and metas-
tases (blue) appeared.Head & Neck Oncology 2009, 1:31 http://www.headandneckoncology.org/content/1/1/31
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Table 1: Overview of published cases of ameloblastic carcinoma of the maxilla in 60 years (1948  2008) (DF: disease free, nm: not 
mentioned, DOD: dead of disease)
Author Year Sex Age treatment metastases Local recurrence Follow-up 
(months)
DOD
Grimes OF [8] 1948 f 46 Surgical excison lung 120 NM
Eda S [9] 1972 f 44 Surgical excision Submand. LN, lung, 
vertebra
6 times 121 DOD
Krempien B [10] 1979 m 5 Surgical excision lung 144 DF
Daramola JO [11] 1980 m 22 Surgical excision, 
radiotherapy, 
chemotherapy
lung 0 NM
Madiedo G [12] 1981 m 49 Surgical excision,
chemotherapy
2 times (12 m, 20 m) 60 DOD
Anderson E [13] 1986 m 73 Surgical excision 48 m 0 NM
Nadimin H [14] 1987 f 15 Surgical excision 0 NM
Corio RL [15] 1987 m 15 Surgical excision 0 NM
Inoue N [16] 1988 f 51 Surgical excision lung 132 m recurrence 0
McClatchey KD [17] 1989 f 77 Surgical excision 24 alive
Lee L [18] 1990 m 56 Surgical excision,
radiotherapy
lung 5 m 7 DOD
Lolachi CM [19] 1995 f 82 Surgical excision 0 NM
Ingram EA [20] 1996 m 83 Surgical excision 24 alive
Infante-Cossio P [21] 1998 f
m
m
69
77
64
Surgical excision, 
radiotherpay
Surgical excision
Surgical excision, 
radiotherapy
brain 60
7
36
alive
DOD
alive
Sastre J [22] 2002 m 40 Surgical excision 24 alive
Avon SL [23] 2003 m 68 Surgical excision no No 120 alive
Zwahlen RA [24] 2003 m 44 Surgical excison, 
Radiotherapy, 
Chemotherapy 
(palliative)
Cardial, pulmonal, 
cerebral
2 times 156 DOD
Dhir K [5] 2003 m 72 Surgical excision 20 alive
Goldenberg D [25] 2004 m 72 Surgical excision, 
radiotherapy
NM
Philip MP [26] 2005 m
m
70
56
Surgical excision,
Radiotherapy
Surgical excison, 
radiotherapy
40
8
Alive
aliveHead & Neck Oncology 2009, 1:31 http://www.headandneckoncology.org/content/1/1/31
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What treatment armamentarium do we have when deal-
ing with this entity? It is well accepted that maxillary
ameloblastomas should be treated as radically as possible
due to the spongy maxillary bone architecture. This struc-
ture may facilitate the spread of the tumour and may lead
to infiltration of adjacent vital structures. In contrast to
this, the speed of growth in the mandible is decelerated
due to the thick and compact bone structure [3].
Curettage of maxillary ameloblastomas is known to be
associated with recurrence in almost 100% of cases [7]. A
surgical resection with 1015 mm margin free of tumour is
recommended [34], even though the extent of the resec-
tion may be limited related to adjacent pivotal anatomical
structures, particularly in the maxilla. Especially in these
kinds of localisations it is of utmost importance to be as
radical as possible to control recurrence and potential
degeneration into ameloblastic carcinoma. Regular fol-
low-up and CT- or MRI controls, in particular in maxillary
ameloblastomas, are broadly accepted among clinicians.
Controversy still exists regarding its treatment: some
authors have suggested radiotherapy [5,20,21] while oth-
ers [35,36] doubt its effectiveness. Most of the ameloblas-
tic carcinomas are intraosseous; therefore, the
effectiveness of radiation therapy must be considered crit-
ically. Philip et al. (2005) [26] suggested to apply adju-
vant radiotherapy in patients with positive resection
Yazici N [27] 2006 m 10 Surgical excision 6 alive
Benlyarzid A [28] 2007 m 90 Surgical excision 25 DOD
Ward BB [4] 2007 m 64 Surgical excision 30 alive
Table 1: Overview of published cases of ameloblastic carcinoma of the maxilla in 60 years (1948  2008) (DF: disease free, nm: not 
mentioned, DOD: dead of disease) (Continued)
Table 2: Classifications of ameloblastic carcinoma by Elzay (1982) and Slootweg & Müller (1984) and the novel classification
Type Elzay (1982)[32] Slootweg & Müller (1984)[33] Kruse et al.(2009)
1 Arising from an odontogenic 
cyst
Primary intraosseous carcinoma ex odontogenic cyst Malignant ameloblastoma
1a - - Metastase with features of an ameloblastoma 
(well differentiated)
1b - - Metastase with malignant features 
(poorly differentiated)
2A r i s i n g  f r o m  a n  
ameloblastoma
Ameloblastic carcinoma arising from an 
ameloblastoma
2a Well differentiated 
(malignant ameloblastoma)
Malignant ameloblastoma Without metastase
2b Poorly differentiated 
(ameloblastic carcinoma)
Ameloblastic carcinoma, arising de novo, ex 
ameloblastoma or ex odontogenic cyst
Metastase with features of an ameloblastoma 
(well differentiated)
2c Metastase with malignant features 
(poorly differentiated)
3A r i s i n g   de novo Primary intraosseous carcinoma de novo Ameloblastic carcinoma with unknown origin 
histology
3a No keratinizing No keratinizing Without metastase
3b Keratinizing Keratinizing Metastase with features of an ameloblastoma 
(well differentiated)
3c Metastase with malignant features 
(poorly differentiated)Head & Neck Oncology 2009, 1:31 http://www.headandneckoncology.org/content/1/1/31
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margins, multiple positive lymph nodes, extracapsular
spread, perineural invasion, and in patients where salvage
surgery would be inefficient. Reports about chemotherapy
regimens in ameloblastic carcinoma are rare. In the
present evidence based review only 3 patients showing a
progressive disease were treated with chemotherapy, and
(they both) all of them died.
With respect to aetiology, differentiation from ameloblas-
tomas and an association with recurrence relating to mul-
tiple surgical procedures have been discussed [33].
Among all the reviewed cases, 27% presented at first his-
topathologic diagnosis as a follicular or plexiform amel-
oblastoma and secondarily as an ameloblastic carcinoma.
The lack of non evidence-based study designs represents a
major shortcoming of the here presented evidence based
literature review. This prevents to collect information in a
standardised manner, however, is in a way to understand
due to the rarity of this pathologic entity. Considering the
limitations of this study, a remarkable aggressiveness of
this pathologic entity could be detected, even though
there were considerable differences in respect to the treat-
ment protocols in terms of surgery, postoperative follow-
up and period of follow-up among the reviewed studies.
The authors suggest that in performing multicenter stud-
ies dealing with such rare entities, it would be easier to
develop treatment protocols, simply by pooling the cases
and experiences of such rare entities.
To provide more information about the biological behav-
iour of ameloblastic carcinomas, Carinci F et al (2004)
[37] described their first genetic portrait. Yet more studies
will have to be performed before, apart from surgery, spe-
cific adjuvant treatment strategies may be implemented.
This novel classification might be a step on the ladder to
specify more accurately the original nature of this carci-
noma.
Conclusion
The novel classification considers the unknown origin as
well as primary ameloblastomas with metastases and their
histopathological features of malignancy without previ-
ous evidence of malignancy in the primary localization.
In cases of maxillary ameloblastomas, a radical resection
should be performed in order to prevent recurrence and
development of malignancy. Patients with maxillary
ameloblastomas should undergo a life-long follow-up
including regular CT or MRI scans, for early detection of
recurrence. For the staging procedure PET scan or chest CT
should be performed in order to detect pulmonary metas-
tases. In cases with maxillary ameloblastic carcinoma, a
neck dissection should only be performed in the presence
of clinically positive lymph nodes.
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